ANAREX TABLET

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

ORPHENADRINE CITRATE; Paracetamol

Boleh didapati daripada:

DUOPHARMA MANUFACTURING (BANGI) SDN BHD

INN (Nama Antarabangsa):

ORPHENADRINE CITRATE; Paracetamol

Unit dalam pakej:

100 Tablet Tablets; 30 Tablet Tablets; 500 Tablet Tablets; 1000 Tablet Tablets

Dikeluarkan oleh:

DUOPHARMA MANUFACTURING (BANGI) SDN BHD

Risalah maklumat

ANAREX TABLET
Orphenadrine citrate / Paracetamol (35mg / 450mg)
1
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_
WHAT IS IN THIS LEAFLET
1.
What Anarex Tablet is used for
2.
How Anarex Tablet works
3.
Before you use Anarex Tablet
4.
How to use Anarex Tablet
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of Anarex
Tablet
8.
Product Description
9.
Manufacturer and Product
Registration Holder
10.
Date of revision
WHAT ANAREX TABLET
IS USED FOR
Anarex Tablet is used to relieve mild to
moderate pain and discomfort related to
conditions that affect muscles and bones.
Your doctor may have prescribed Anarex
Tablet for another purpose.
Ask
your
doctor
if
you
have
any
questions about why this medicine has
been prescribed for you.
HOW ANAREX TABLET
WORKS
Orphenadrine
citrate
is
a
muscle
relaxant. It acts in the nervous system to
produce muscle relaxant effects.
Paracetamol is used to treat or prevent
pain and reduce fever.
BEFORE YOU USE ANAREX TABLET
-
_When you must not use it _
Do not take Anarex Tablet if you have
had an allergic reaction to orphenadrine
citrate,
paracetamol
or
other
similar
medicine, or to any of the ingredients
listed at the end of this leaflet.
_ _
Do not take Anarex Tablet if you have
any of the following:
•
high pressure in the eye
•
obstruction
of
small
intestine
or
stomach
•
stomach ulcer
•
failure of lower esophagus opening
up during swallowing
•
enlarged prostate
•
obstructions at the bladder neck
•
myasthenia
gravis
(a
disease
of
muscles
causing
drooping
eyelids,
double vision, difficulty in speaking
and
swallowing,
and,
sometimes
muscle
weakness
in
the
arms
or
legs).
Do not take Anarex Tablet:
•
after the expiry date on the pack;
•
if
the
packaging
shows
signs
of
tampering;
•
unless advised by your doctor
Do not give this medicine to a child
under the age of 12 years. Safety and
effectiveness in children younger than
12 years have not been established.
_ _
-
_Before you start use it _
Tell your doctor or pharmacist if:
•
you
have
allergies
to
any
ot

Ciri produk

Because of the mild anticholinergic effect of orphenadrine, Anarex
should not be used
in patients with glaucoma, duodenal or pyloric obstruction, stenosing
peptic ulcer,
achalasia, prostatic hypertrophy, or obstructions at the bladder neck.
Anarex is also
contraindicated in patients with myasthenia gravis and in patients
known to be
sensitive to paracetamol or orphenadrine.
Anarex Tablet should be given with care to active alcoholics, and
patients with hepatic
diseases or viral hepatitis as there is an increased risk of
hepatotoxicity. Risk of adverse
renal effects may be increased with prolonged use of high doses of
Anarex Tablet in
patients with renal function impairment. It should be used cautiously
in patients with
cardiac disease, arrhythmias and tachycardia as ophenadrine may cause
tachycardia.
CNS depression may also be exarcebated. Blood count, hepatic and renal
function
determinations may be required at periodic intervals during prolonged
or high-dose
therapy since the safety of continuous long-term use has not been
established.
Paracetamol may cause falsely decreased values in blood glucose
determinations when
the
glucose
oxidase/peroxidase
method
is
used,
but
probably
not
when
the
hexokinase/glucose-6-phosphate dehydrohenase (G6PD) method is used.
Values may also be falsely increased when certain instruments are used
in glucose
analysis if high paracetamol concentrations are present. Paracetamol
may cause
false-positive results in qualitative screening tests of serum
5-Hydroxyindoleacetic acid
(5-HIAA) using nitrosonaphthol reagent; the quantitative test is
unaffected.
Administration of paracetamol prior to the pancreatic function test
using bentiromide
will invalidate test results because paracetamol is also metabolized
to an arylamine and
will thus increase the apparent quantity of para-aminobenzoic acid
(PABA) recovered;
it
is
recommended
that
paracetamol
be
discontinued
at
least
3
days
prior
to
administration of bentiromide. Falsely increased values are also
obtained when the
phosphotungstate uric